Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

NCT04835519 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Relapse Leukemia
Refractory Acute Myeloid Leukemia

Interventions

BIOLOGICAL: chimeric antigen receptor T cell

Sponsor

Beijing Boren Hospital